News

Deal Announcements

Eiger Bio Adds More Venture Capital Funds

Thursday, April 28, 2011 5:54:00 AM PDT | VentureDeal Staff
Palo Alto, California  --  Eiger Biopharmaceuticals has landed $3.55 million in additional venture capital funding, according to an SEC regulatory filing.

Eiger is focused on developing antiviral agents in the treatment of hepatitis.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Eiger is still seeking an additional $1.45 million in funding.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1